Kymera Therapeutics (KYMR) Cash from Operations (2019 - 2026)
Kymera Therapeutics (KYMR) reported Cash from Operations of 88840000.0 for Q1 2026, down 12.24% year-over-year from 101233602.07 in Q1 2025, and down 33.1% quarter-over-quarter from 66747000.0 in Q4 2025.
Kymera Therapeutics (KYMR) Cash from Operations (2019 - 2026) Analysis & Trends
Kymera Therapeutics (KYMR) has 8 years of Cash from Operations data on file, last reported at 88840000.0 in Q1 2026.
- Cash from Operations for Q1 2026 came in at 88840000.0, down 12.24% year-over-year; the trailing twelve-month figure through Mar 2026 was 242581000.0 (down 3.64% YoY), and the FY2025 annual result was 232891000.0, down 19.74% from the prior year.
- Cash from Operations declined to 88840000.0 in Q1 2026 per KYMR's latest filing, from 66747000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 8045000.0 in Q4 2023 and troughed at 88840000.0 in Q1 2026.
- A 5-year average of 45420176.47 and a median of 40295000.0 in 2022 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2023 and 2024: Cash from Operations jumped 120.35% in 2023, then tumbled 867.98% in 2024.
- A 5-year view of Cash from Operations shows it stood at 39536000.0 in 2022, then jumped by 120.35% to 8045000.0 in 2023, then plunged by 867.98% to 61784000.0 in 2024, then slipped by 8.03% to 66747000.0 in 2025, then slumped by 33.1% to 88840000.0 in 2026.
- Business Quant data shows KYMR's Cash from Operations at 88840000.0 in Q1 2026, 66747000.0 in Q4 2025, and 27110000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.49 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.43 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Kymera Therapeutics | 8.84 Bn | 8.19 Bn | - | -88.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -88.84 Mn |
| Mar 31, 2026 | -88.84 Mn |
| Dec 31, 2025 | -66.75 Mn |
| Dec 31, 2025 | -66.75 Mn |
| Sep 30, 2025 | -27.11 Mn |
| Sep 30, 2025 | -27.11 Mn |
| Jun 30, 2025 | -59.88 Mn |
| Jun 30, 2025 | -59.88 Mn |
| Mar 31, 2025 | -79.15 Mn |
| Mar 31, 2025 | -79.15 Mn |
| Dec 31, 2024 | -61.78 Mn |
| Dec 31, 2024 | -61.78 Mn |
| Sep 30, 2024 | -50.19 Mn |
| Sep 30, 2024 | -50.19 Mn |
| Jun 30, 2024 | -42.94 Mn |
| Jun 30, 2024 | -42.94 Mn |
| Mar 31, 2024 | -39.59 Mn |
| Mar 31, 2024 | -39.59 Mn |
| Dec 31, 2023 | 8.05 Mn |
| Dec 31, 2023 | 8.05 Mn |